Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Silence Therapeutics plc SLN
$6.10
-$0.11 (-1.77%)
На 18:03, 12 мая 2023
+285.25%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
263478727.00000000
-
week52high
17.99
-
week52low
4.55
-
Revenue
17501000
-
P/E TTM
-12
-
Beta
0.72002800
-
EPS
-1.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 04:00
Описание компании
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 31 мар 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 22 мар 2022 г. |
| Chardan Capital | Buy | Buy | 17 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | 09 дек 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 06 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Zacks Investment Research
18 янв 2023 г. в 10:33
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zacks Investment Research
04 янв 2023 г. в 13:32
Silence Therapeutics PLC Sponsored ADR (SLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
03 янв 2023 г. в 07:00
LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. PT.
Silence Therapeutics: Excellent Data In A Cardiovascular Indication
Seeking Alpha
06 дек 2022 г. в 02:19
SLN is a gene silencing therapy developer. SLN produced excellent data from its lead candidate.
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha
17 мар 2022 г. в 14:02
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript